Professor of Cardiovascular Medicine, Honorary Consultant Cardiologist. Specialist adult cardiovascular care: putting research into practice to benefit patients
Joined August 2016
- Tweets 19,022
- Following 1,681
- Followers 13,444
- Likes 36,777
2,691 Photos and videos
Pinned Tweet
3 Aug 2025
Clinical Lead for #MINAP , the largest continuous collection single healthcare system #heartattack registry.
33
7,031
Prof Chris P Gale retweeted
Jun 12
Fabulous exhibition in Paris last year by Yorkshire’s very own, RIP David Hockney
1
7
49
1,015
A FeAsibility items Checklist for assessing implementation characTeristics of patient reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): development and evaluation via @cpgale3 et al
sciencedirect.com/science/ar…
1
5
4
642
Jun 11
Editorial @EJPCEiC; LDL-C reduction & saphenous vein graft patency after CABG surgery academic.oup.com/eurjpc/arti…
1
1
5
1,696
🤔, continue writing a grant or spend the same time reviewing grant applications; what do you suggest?
88%
Write your grant
12%
Review the grants
0%
Do neither
0%
Only you can decide
8 votes • Final results
1
1
592
Prof Chris P Gale retweeted
CLINCAL COMMENTARIES: Should beta-blockers be withheld after myocardial infarction?
John Cleland, Ben Hurdus, & Chris Gale explore recent trial results, including what this tell us about the practice of evidence-based medicine
academic.oup.com/cardiovascr…
#CardiovascularResearch
4
9
522
Jun 11
Derivation & Definitions of Clinical Study Variables for Multiple Long Term Conditions in Patients with #COPD: Protocol for a Modified Delphi Methods & Consensus Study on Behalf of the International Cardiovascular & Respiratory Alliance dovepress.com/
2
252
🏆 Trainees — submit your best coronary complication case for the BCIS Interventional Trainees Conference 2026!
Top 3 cases presented at the Trainees Course. Award for the winner.
Max 12 slides consultant cover note. Deadline: 31 July, 5pm 👇
bcis.org.uk/news/bcis-interv…
#BCIS #InterventionalCardiology #Cardiology
3
3
406
Prof Chris P Gale retweeted
How does the ESC evaluate the evidence underpinning its Guideline recommendations?
Join the ESC webinar on 19 June to learn about the revised Level of Evidence framework and what it means for future guidelines and clinical practice ow.ly/C0WV50Z9iV5
As CPG Committee Co-Chairs Ulf Landmesser and Stefan James state: “The revised Level of Evidence framework represents an important step towards greater transparency and consistency in evaluating evidence for guideline recommendations."
#ESCGuidelines #Cardiology #EvidenceBasedMedicine #ESCWebinar @rishibansalMD
4
4
1,454
Prof Chris P Gale retweeted
May 28
Even before diabetes develops, dysglycaemia may increase AF risk. ⚠️
A meta-analysis including 26.4 million participants showed that prediabetes was associated with ⬆️15% risk of AF, supporting a dose–response relationship across glucose levels.
🔗doi.org/10.1093/eurjpc/zwag2…
25
61
9,930
Prof Chris P Gale retweeted
Aortic stenosis remains underdiagnosed and undertreated – but earlier recognition and streamlined referral pathways can make a real difference for patients.
Explore the new #AortiCare Toolkit from the ESC and ACNAP, designed to support healthcare professionals with practical guidance on diagnosis, treatment and intervention in aortic valve disease.
🔗 Explore the toolkit ow.ly/g5UJ50Z9g4u
#ACNAP #Aorticare #Aorticstenosis @ACNAPPresident
5
14
1,451
“Diastolic dysfunction was as common in pre-diabetes as in diabetes & was mainly associated with central adiposity, hypertension & coronary atherosclerosis” openheart.bmj.com/content/13…
3
6
748
Prof Chris P Gale retweeted
How often do we fully capture cardiovascular risk in patients with chronic kidney disease?
The session on "Chronic kidney disease and cardiovascular disease: risk assessment and reduction in the multimorbid patient" highlights a crucial challenge in clinical practice.
Patients with CKD face a significantly increased risk of cardiovascular disease, driven by both traditional risk factors (e.g. hypertension, diabetes) and kidney-specific mechanisms such as inflammation and metabolic disturbances.
1
2
2
3,316
Finerenone in CKD without diabetes led to a slower decrease in the eGFR than placebo over 32 months at the expense of ~4% absolute increase in rate of hyperkalaemia. nejm.org/doi/full/10.1056/NE…
2
5
728
More variation. This time general practice prescribing of Inclisiran at the sub-ICB level, March 2026.
4
6
10
7,962
Prof Chris P Gale retweeted
Jun 5
Individual hearts: computational models for improved management of cardiovascular disease bit.ly/4fCXgWD
3
5
1,019
May 22
Encouraging all NHS Trusts to participate in the PROFID-EHRA randomised clinical trial testing the effectiveness of primary prevention ICD after #heartattack in severe #heartfailure on optimised pharmacotherapies.
Contact me if you would like to join.
7
24
48
33,322
“The success of AF screening hinges on reaching at-risk individuals & selecting effective monitoring strategies. Precision-based approaches & AI-guided targeting may ensure that screening yields clinical & economical benefit.”
… hence #FINDAF
heart.bmj.com/content/early/…
1
2
449
Geographic variation (I would say a ‘hot spot’) of prescribing Wegovy by general practice at sub ICB level in the NHS of England, March 2026
share.google/E4raIviefoND5K…
4
4
14
7,324
Prof Chris P Gale retweeted
Why applied clinical research is not just "a thing". It's an integral part of healthcare👇🏻 #noexcuse support trials!
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
1
7
1,043